CN101134038B - 缓释的口服给药组合物 - Google Patents

缓释的口服给药组合物 Download PDF

Info

Publication number
CN101134038B
CN101134038B CN2007101488421A CN200710148842A CN101134038B CN 101134038 B CN101134038 B CN 101134038B CN 2007101488421 A CN2007101488421 A CN 2007101488421A CN 200710148842 A CN200710148842 A CN 200710148842A CN 101134038 B CN101134038 B CN 101134038B
Authority
CN
China
Prior art keywords
dechlorloratadine
pharmaceutically acceptable
double
layer
solid composite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007101488421A
Other languages
English (en)
Chinese (zh)
Other versions
CN101134038A (zh
Inventor
W·-K·P·曹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22629073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101134038(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN101134038A publication Critical patent/CN101134038A/zh
Application granted granted Critical
Publication of CN101134038B publication Critical patent/CN101134038B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2007101488421A 1999-12-20 2000-12-20 缓释的口服给药组合物 Expired - Fee Related CN101134038B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17275299P 1999-12-20 1999-12-20
US60/172,752 1999-12-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB001373560A Division CN100415223C (zh) 1999-12-20 2000-12-20 缓释的口服给药组合物

Publications (2)

Publication Number Publication Date
CN101134038A CN101134038A (zh) 2008-03-05
CN101134038B true CN101134038B (zh) 2013-11-06

Family

ID=22629073

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2008101283750A Pending CN101322708A (zh) 1999-12-20 2000-12-20 缓释的口服给药组合物
CN2007101488421A Expired - Fee Related CN101134038B (zh) 1999-12-20 2000-12-20 缓释的口服给药组合物
CNB001373560A Expired - Lifetime CN100415223C (zh) 1999-12-20 2000-12-20 缓释的口服给药组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA2008101283750A Pending CN101322708A (zh) 1999-12-20 2000-12-20 缓释的口服给药组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB001373560A Expired - Lifetime CN100415223C (zh) 1999-12-20 2000-12-20 缓释的口服给药组合物

Country Status (38)

Country Link
US (3) US6709676B2 (enExample)
EP (3) EP2100600A1 (enExample)
JP (2) JP5158919B2 (enExample)
KR (2) KR20010062543A (enExample)
CN (3) CN101322708A (enExample)
AR (1) AR027034A1 (enExample)
AT (2) ATE329584T1 (enExample)
AU (2) AU2276801A (enExample)
BR (1) BR0005938A (enExample)
CA (1) CA2329172C (enExample)
CO (1) CO5251421A1 (enExample)
CY (3) CY1105231T1 (enExample)
CZ (1) CZ302471B6 (enExample)
DE (3) DE122008000001I1 (enExample)
DK (2) DK1110543T3 (enExample)
EC (1) ECSP003835A (enExample)
ES (2) ES2261158T3 (enExample)
FR (1) FR08C0004I2 (enExample)
HU (1) HU227538B1 (enExample)
IL (1) IL140451A (enExample)
LU (1) LU91403I2 (enExample)
MX (1) MXPA00012957A (enExample)
MY (1) MY128658A (enExample)
NL (1) NL300328I2 (enExample)
NO (1) NO331653B1 (enExample)
NZ (1) NZ509034A (enExample)
PE (1) PE20010952A1 (enExample)
PL (1) PL209401B1 (enExample)
PT (2) PT1674084E (enExample)
RU (1) RU2284182C9 (enExample)
SA (2) SA06270068B1 (enExample)
SG (2) SG149667A1 (enExample)
SI (2) SI1674084T1 (enExample)
SK (1) SK287105B6 (enExample)
TR (1) TR200003788A2 (enExample)
TW (1) TWI222885B (enExample)
WO (1) WO2001045676A2 (enExample)
ZA (1) ZA200007714B (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287105B6 (sk) * 1999-12-20 2009-12-07 Schering Corporation Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
HU226998B1 (en) * 2000-11-23 2010-04-28 Richter Gedeon Nyrt Desloratadine hemisulphate, process for the preparation thereof and pharmaceutical compositions containing the same
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
HU230435B1 (hu) 2001-01-26 2016-06-28 Merck Sharp & Dohme Corp Szubsztituált azetidinon vegyületek alkalmazása szitoszterinémia kezelésére
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
JP4318899B2 (ja) * 2001-08-27 2009-08-26 第一三共ヘルスケア株式会社 抗感冒剤
JP2009132734A (ja) * 2001-08-27 2009-06-18 Daiichi Sankyo Healthcare Co Ltd 抗感冒剤
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CA2460340C (en) 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
JP4320217B2 (ja) * 2002-07-10 2009-08-26 剤盛堂薬品株式会社 鼻炎用経口製剤
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
MXPA05004811A (es) 2002-11-06 2005-07-22 Schering Corp Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
US7863287B2 (en) * 2002-12-18 2011-01-04 Wyeth Llc Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US20040242619A1 (en) * 2003-03-12 2004-12-02 Toth Zoltan G. Processes for preparation of polymorphic forms of desloratadine
WO2005046650A1 (en) * 2003-11-12 2005-05-26 Glenmark Pharmaceuticals Limited Pharmaceutical formulation containing muscle relaxant and cox-ii inhibitor
US7955620B2 (en) 2003-12-23 2011-06-07 Sun Pharmaceutical Industries Limited Stable oral composition
US20110081415A1 (en) * 2005-03-10 2011-04-07 Taisho Pharmaceutical Co., Ltd Coating apparatus
ES2398209T3 (es) * 2005-03-10 2013-03-14 Taisho Pharmaceutical Co., Ltd. Aparato para preparar un agente recubierto de azúcar
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20070004671A1 (en) * 2005-05-20 2007-01-04 Agarwal Sudeep K Stable desloratadine compositions
CA2547274A1 (en) * 2005-05-20 2006-11-20 Dr. Reddy's Laboratories Limited Stable desloratadine compositions
US20070014855A1 (en) * 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions
RU2008113439A (ru) 2005-09-09 2009-10-20 Лабофарм Инк. (CA) Композиции с замедленным высвобождением лекарственного средства
US20110145009A1 (en) * 2005-11-30 2011-06-16 Jung Edward K Y Methods and systems related to transmission of nutraceutical associatd information
US8068991B2 (en) * 2005-11-30 2011-11-29 The Invention Science Fund I, Llc Systems and methods for transmitting pathogen related information and responding
US20080004905A1 (en) * 2006-06-28 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for analysis of nutraceutical associated components
US8340944B2 (en) * 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20070289258A1 (en) * 2006-06-14 2007-12-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Individualized pharmaceutical selection and packaging
US20070174128A1 (en) * 2005-11-30 2007-07-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7827042B2 (en) * 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US7927787B2 (en) * 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US20080114577A1 (en) * 2005-11-30 2008-05-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems associated with nutraceutical related assays
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US20070124219A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized nutraceutical selection and packaging
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20080052114A1 (en) * 2005-11-30 2008-02-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods related to nutraceuticals
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US10296720B2 (en) * 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20080033763A1 (en) * 2005-11-30 2008-02-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems related to receiving nutraceutical associated information
EP1988893A4 (en) * 2006-02-22 2010-05-26 Orchid Chemicals & Pharm Ltd FORMULATION CONTAINING DESLORATADINE STABILIZED USING CYCLODEXTRIN
CA2541045A1 (en) * 2006-03-24 2007-09-24 Pharmascience Inc. A descarbonylethoxyloratadine containing pharmaceutical composition
TWI405567B (zh) * 2006-06-01 2013-08-21 Merck Sharp & Dohme 持續釋放脫羥腎上腺素之醫藥組合物
CN104161736A (zh) 2006-06-01 2014-11-26 Msd消费保健品公司 包含去氧肾上腺素的缓释药物制剂
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
TW200808376A (en) * 2006-06-01 2008-02-16 Schering Corp Phenylephrine pulsed release formulations and pharmaceutical compositions
US7718649B1 (en) * 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
BRPI0812784A2 (pt) * 2007-06-01 2014-12-02 Schering Plough Healthcare Composição farmacêutica compreendendo um substrato e um revestimento contendo um ingrediente ativo e polivinilálcool
TWI400042B (zh) * 2007-06-08 2013-07-01 Tci Co Ltd 食品錠劑
EP2203166B1 (en) 2007-10-16 2015-05-06 Paladin Labs Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
EP2219612A4 (en) 2007-12-17 2013-10-30 Paladin Labs Inc FORMULATION WITH TAXED RELEASE AND ABUSE PROTECTION
CA2746888C (en) 2008-12-16 2015-05-12 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
WO2012151562A1 (en) 2011-05-04 2012-11-08 Intellikine, Llc Combination pharmaceutical compositions and uses thereof
BR102012030828A2 (pt) 2012-12-03 2014-09-16 Ems Sa Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso
AU2017331369B2 (en) 2016-09-26 2019-11-21 The Procter & Gamble Company Extended relief dosage form
US10463656B2 (en) 2017-01-05 2019-11-05 Iowa State University Research Foundation, Inc. Methods and compositions for prevention of feedlot bovine respiratory disease
CN109966254B (zh) * 2017-12-28 2021-06-01 广州医药研究总院有限公司 复方地氯伪麻缓释小丸及其制备方法
CN108578406A (zh) * 2018-04-18 2018-09-28 曹建华 一种用于过敏性鼻炎治疗的组合物
US11806320B2 (en) * 2020-02-19 2023-11-07 Endo Ventures Limited Isoproterenol compositions and methods
CN113230235B (zh) * 2021-04-15 2022-11-11 海南普利制药股份有限公司 含地氯雷他定的复方缓释胶囊及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100675A (en) * 1989-05-03 1992-03-31 Schering Corporation Sustained release tablet comprising loratadine, ibuprofen and pseudoephedrine
CN1089471A (zh) * 1992-10-23 1994-07-20 先灵公司 稳定的延长释放口服组合物
CN1235545A (zh) * 1996-10-31 1999-11-17 先灵公司 含有氯雷他定和减充血剂的用于治疗哮喘的组合物

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3940485A (en) 1973-12-12 1976-02-24 Levinson Harold N Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds
US4008796A (en) 1974-03-26 1977-02-22 General Concrete Of Canada Limited Control method for feeding items on a conveyor
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
WO1985003707A1 (en) 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
SE8404467D0 (sv) 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4804666A (en) 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
JPS6396126A (ja) * 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd 安定化組成物
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4777170A (en) 1987-02-03 1988-10-11 Heinrich William A Method to prevent and treat the signs and symptoms of motion sickness
GB8707421D0 (en) 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US4863931A (en) 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US5019591A (en) 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
IL98572A (en) 1990-06-22 1995-07-31 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene, piperidylidene and piperazine compositions an methods of use
CA2098198A1 (en) 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
PT100502A (pt) 1991-05-20 1993-08-31 Alza Corp Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
ES2042421B1 (es) 1992-05-22 1994-08-01 Uriach & Cia Sa J Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina.
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
JP2646972B2 (ja) 1993-11-01 1997-08-27 日本電気株式会社 多ビットメモリ
DE4442999A1 (de) 1994-12-02 1996-06-05 Hexal Pharma Gmbh Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US7214683B1 (en) * 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US7211582B1 (en) * 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
TW522014B (en) * 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
US5900421A (en) 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6506767B1 (en) 1997-07-02 2003-01-14 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine
DK0998272T3 (da) * 1997-08-26 2003-08-25 Aventis Pharma Inc Farmaceutisk præparat til kombinationen piperidinoalkanoldekongestivum
WO1999021556A1 (en) 1997-10-29 1999-05-06 J-Med Pharmaceuticals, Inc. Antihistamine/decongestant regimens for treating rhinitis
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
PT1380297E (pt) * 1998-07-10 2009-07-06 Schering Corp Composições orais de 8-cloro-6,11-di-hidro-11-(4- piperidilideno)-5h-benzo[5,6]ciclo-hepta[1,2-b]piridina
US6423721B1 (en) * 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US6051585A (en) 1998-12-07 2000-04-18 Weinstein; Robert E. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6100274A (en) 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
SK287105B6 (sk) * 1999-12-20 2009-12-07 Schering Corporation Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
WO2001045668A2 (en) 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
AR028502A1 (es) * 2000-02-03 2003-05-14 Schering Corp Tratamiento de condiciones inflamatorias alérgicas
ATE272619T1 (de) * 2000-05-19 2004-08-15 Alcon Inc Anilin-disulfid-derivate zur behandlung allergischer erkrankungen
US6599913B1 (en) 2001-06-29 2003-07-29 Schering Corporation Treating allergic and inflammatory conditions
US6679463B1 (en) * 2003-06-11 2004-01-20 Kye Systems Corp. Support with multi-stage clamping mechanism
US7955620B2 (en) * 2003-12-23 2011-06-07 Sun Pharmaceutical Industries Limited Stable oral composition
EP1778195A2 (en) * 2004-07-16 2007-05-02 Cipla Limited Anti-histaminic composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100675A (en) * 1989-05-03 1992-03-31 Schering Corporation Sustained release tablet comprising loratadine, ibuprofen and pseudoephedrine
CN1089471A (zh) * 1992-10-23 1994-07-20 先灵公司 稳定的延长释放口服组合物
CN1235545A (zh) * 1996-10-31 1999-11-17 先灵公司 含有氯雷他定和减充血剂的用于治疗哮喘的组合物

Also Published As

Publication number Publication date
RU2284182C9 (ru) 2007-11-20
TWI222885B (en) 2004-11-01
CY1105231T1 (el) 2010-03-03
BR0005938A (pt) 2001-11-27
PE20010952A1 (es) 2001-09-25
EP1674084B1 (en) 2009-09-02
CZ302471B6 (cs) 2011-06-08
KR20080044214A (ko) 2008-05-20
CY1109636T1 (el) 2014-08-13
US7618649B2 (en) 2009-11-17
EP1110543A2 (en) 2001-06-27
ES2330873T3 (es) 2009-12-16
WO2001045676A2 (en) 2001-06-28
DE60028710D1 (de) 2006-07-27
AU777419B2 (en) 2004-10-14
ATE441404T1 (de) 2009-09-15
NO20006503L (no) 2001-06-21
PL344714A1 (en) 2001-07-02
DE60028710T2 (de) 2007-06-14
US6709676B2 (en) 2004-03-23
SK287105B6 (sk) 2009-12-07
PT1110543E (pt) 2006-08-31
DE60042904D1 (de) 2009-10-15
IL140451A (en) 2011-11-30
ATE329584T1 (de) 2006-07-15
EP1110543B1 (en) 2006-06-14
PT1674084E (pt) 2009-10-19
FR08C0004I2 (fr) 2009-01-15
US20100021542A1 (en) 2010-01-28
MY128658A (en) 2007-02-28
ES2261158T3 (es) 2006-11-16
EP1110543A3 (en) 2001-08-29
MXPA00012957A (es) 2003-06-19
SA01210740A (ar) 2005-12-03
EP1674084A3 (en) 2006-07-05
TR200003788A3 (tr) 2001-07-23
HU227538B1 (en) 2011-08-29
CN101134038A (zh) 2008-03-05
US20030031713A1 (en) 2003-02-13
SI1674084T1 (sl) 2010-01-29
FR08C0004I1 (enExample) 2008-03-21
AU7244200A (en) 2001-06-21
SG183573A1 (en) 2012-09-27
SG149667A1 (en) 2009-02-27
NZ509034A (en) 2002-09-27
SA01210740B1 (ar) 2006-10-31
NL300328I1 (nl) 2008-03-03
US20040097536A1 (en) 2004-05-20
EP2100600A1 (en) 2009-09-16
KR20010062543A (ko) 2001-07-07
CZ20004813A3 (cs) 2001-08-15
PL209401B1 (pl) 2011-08-31
ECSP003835A (es) 2002-02-25
NO20006503D0 (no) 2000-12-20
CY2007031I1 (el) 2009-11-04
CY2007031I2 (el) 2009-11-04
DE122008000001I1 (de) 2008-04-17
DK1674084T3 (da) 2009-12-14
HUP0004989A2 (hu) 2004-05-28
SI1110543T1 (sl) 2006-10-31
HUP0004989A3 (en) 2008-04-28
HK1090840A1 (en) 2007-01-05
HK1034452A1 (en) 2001-10-26
DK1110543T3 (da) 2006-09-18
CN100415223C (zh) 2008-09-03
RU2284182C2 (ru) 2006-09-27
LU91403I2 (fr) 2008-02-21
CN1302605A (zh) 2001-07-11
CA2329172A1 (en) 2001-06-20
CN101322708A (zh) 2008-12-17
IL140451A0 (en) 2002-02-10
NL300328I2 (nl) 2008-07-01
CA2329172C (en) 2005-10-25
TR200003788A2 (tr) 2001-07-23
HU0004989D0 (enExample) 2001-02-28
AR027034A1 (es) 2003-03-12
JP2008081509A (ja) 2008-04-10
AU2276801A (en) 2001-07-03
NO331653B1 (no) 2012-02-13
ZA200007714B (en) 2001-08-16
JP5158919B2 (ja) 2013-03-06
US8187630B2 (en) 2012-05-29
JP2001206846A (ja) 2001-07-31
SK19662000A3 (sk) 2001-09-11
EP1674084A2 (en) 2006-06-28
SA06270068B1 (ar) 2009-12-23
WO2001045676A3 (en) 2002-01-03
CO5251421A1 (es) 2003-02-28

Similar Documents

Publication Publication Date Title
CN101134038B (zh) 缓释的口服给药组合物
CN101081224B (zh) 稳定的缓释口服给药组合物
HK1125292A (en) Extended release oral dosage composition
HK1034452B (en) Extended release oral dosage composition
HK1090840B (en) Extended release oral dosage composition
HK1130437A (en) Extended release oral dosage composition
HK1141720A (en) Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
HK1034453B (en) Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: new jersey

Applicant after: Schering Corporation

Address before: New Jersey Kai Neal Hill Ping Road No. 2000 at Angelo

Applicant before: SCHERING CORP (US)

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: SCHERING CORP (US) TO: MSD CORP.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131106

Termination date: 20141220

EXPY Termination of patent right or utility model